BioInvent International (BINV) Stock Overview
A clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BINV from our risk checks.
BINV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 28.00 |
| 52 Week High | SEK 50.80 |
| 52 Week Low | SEK 22.70 |
| Beta | -0.10 |
| 1 Month Change | -6.20% |
| 3 Month Change | -22.97% |
| 1 Year Change | -37.01% |
| 3 Year Change | -38.86% |
| 5 Year Change | -31.71% |
| Change since IPO | -97.89% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of BioInvent International AB (publ)'s (STO:BINV) Tunnel And Push Stock Down 26%
Sep 09
BioInvent International AB (publ)'s (STO:BINV) CEO Might Not Expect Shareholders To Be So Generous This Year
Apr 23Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?
Aug 16We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
Apr 09Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Sep 01Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive
Jun 02Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week
Feb 25We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely
Sep 28Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook
Aug 31Shareholder Returns
| BINV | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.4% | 9.8% | 2.7% |
| 1Y | -37.0% | 0.7% | -1.2% |
Return vs Industry: BINV underperformed the Swedish Biotechs industry which returned -1.5% over the past year.
Return vs Market: BINV underperformed the Swedish Market which returned -1.7% over the past year.
Price Volatility
| BINV volatility | |
|---|---|
| BINV Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: BINV has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BINV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 122 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1 clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers.
BioInvent International AB (publ) Fundamentals Summary
| BINV fundamental statistics | |
|---|---|
| Market cap | SEK 1.84b |
| Earnings (TTM) | -SEK 291.95m |
| Revenue (TTM) | SEK 254.29m |
Is BINV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINV income statement (TTM) | |
|---|---|
| Revenue | SEK 254.29m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 254.29m |
| Other Expenses | SEK 546.25m |
| Earnings | -SEK 291.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | -4.44 |
| Gross Margin | 100.00% |
| Net Profit Margin | -114.81% |
| Debt/Equity Ratio | 0% |
How did BINV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 15:15 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioInvent International AB (publ) is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |